Bio-Bridge Science Signs Exclusive Distribution Agreement with Xinhua Surgical Instruments.OAK BROOK, Ill. -- Bio-Bridge Science, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : BGES BGES Belgian Group for Endoscopic Surgery ) today announced that it has entered into an exclusive distribution agreement with Xinhua Surgical Instruments Co., Ltd., located in Shandong, China. Under the agreement, Bio-Bridge Science has been granted exclusive distribution rights for all Xinhua surgical instruments in the United States, which are subject to FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval. Dr. Liang Qiao, Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Bio-Bridge Science said, "We believe that our agreement with Xinhua will enable us to create a revenue stream as we develop our vaccine program. We are pleased to be able to offer Xinhua surgical instruments to potential U.S. customers. Xinhua surgical instruments are manufactured with German technology and expertise, giving them competitive advantages in product surface, corrosion resistance, performance, as well as price. We believe our knowledge of the Chinese and American medical market should allow us to be effective in introducing the products in the United States." About the Company Bio-Bridge Science, Inc. is a biotechnology firm focused on the development of vaccines with broad therapeutic and preventive applications. Through its wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. in Beijing, Bio-Bridge is developing a HIV Vaccine HIV vaccine AIDS As of mid-2005, there is no viable anti-HIV vaccine. See AIDS. , that is expected to enter clinical trials early next year in China. The vaccine, based on exclusive technology co-developed by CEO Liang Qiao, an associate professor at Loyola University Chicago's Stritch School of Medicine This article or section has multiple issues: * It does not cite any references or sources. Please help improve this article by citing reliable sources. * Its notability is in question. If notability cannot be established, this article may be listed for deletion. , is designed to target infection in mucosal tissues, the first type of tissue attacked by HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. . About Xinhua Xinhua Surgical Instruments Co. Ltd. is a world leader in surgical instrument production that is based in Shandong, China Forward Looking Statements This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks defined in this document and in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof. Please refer to SEC filings for additional information and accompanying notes to financial statements. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion